Skeffington Keyna Pidcock
Known title: General CounselCIK: 0001712880
Associated companies
Transaction History
| LIVN | ▲ Buy | Option Exercise | 300 | $0 | 9/15/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 141 | $8K | 9/15/2022 | View on chart |
| LIVN | ▼ Sell | Other | 19 | $0 | 6/30/2022 | View on chart |
| LIVN | ▼ Sell | Other | 9 | $562 | 6/30/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 578 | $0 | 3/30/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 272 | $22K | 3/30/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 1,434 | $0 | 3/30/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 853 | $0 | 3/30/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 401 | $33K | 3/30/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 674 | $55K | 3/30/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 459 | $0 | 3/15/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 216 | $16K | 3/15/2022 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 774 | $0 | 3/1/2022 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 364 | $28K | 3/1/2022 | View on chart |
| LIVN | ▼ Sell | Other | 14 | $1K | 12/31/2021 | View on chart |
| LIVN | ▼ Sell | Other | 7 | $0 | 12/31/2021 | View on chart |
| LIVN | ▼ Sell | Tax Withholding | 142 | $12K | 9/15/2021 | View on chart |
| LIVN | ▲ Buy | Option Exercise | 301 | $0 | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
LivaNova Shares Rise on Barclays Overweight Rating
Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.
LivaNova Shares Rise on Barclays Overweight Rating. Barclays has begun coverage of LivaNova, giving it an overweight rating and a $105 price target. The stock is currently trading near the upper end of its 52‑week range and has been on a 60% three‑year run, which some analysts see as undervalued. Technical indicators show an RSI of 45 and a support level at $78.13, with a support reject signal that may signal a short‑term consolidation.